New weapon against advanced cancers enters human testing
NCT ID NCT07256782
Summary
This study is testing a new drug called QLC5508, given with other cancer medicines, for people with advanced solid tumors. The main goals are to find the safest and most effective dose and to see if the combination can shrink tumors. It will enroll about 444 adults in China who have either run out of standard treatment options or are newly diagnosed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, China
Contact
Conditions
Explore the condition pages connected to this study.